In the present study, inhibitors of both p38 and STAT1 could reduce the induction of iNOS expression and NO production in RASMCs caused by CMS, suggesting that both factors were involved in CMS-mediated iNOS-NO signaling. The gene discussed is NOS2; the disease is congenital myasthenic syndrome.